Market Summary
USD53.09-1.00
Market Closed-1.85%
IART Alerts
IART Stock Price
IART RSI Chart
IART Valuation
IART Price/Sales (Trailing)
IART Profitability
IART Fundamentals
IART Revenue
IART Earnings
Price Action
52 Week Range
40.6767.14
(Low)(High)
Last 7 days
-1.5%
Last 30 days
-9.0%
Last 90 days
-5.8%
Trailing 12 Months
-18.2%
IART Financial Health
IART Investor Care
Peers (Alternatives to Integra LifeSciences Holdings)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 176.3B | 31.5B | -6.84% | -10.46% | 24.46 | 5.6 | 6.85% | 12.06% |
MDT | 104.3B | 30.8B | -7.09% | -24.59% | 25.66 | 3.39 | -3.19% | -17.38% |
SYK | 103.3B | 18.4B | 2.26% | 8.00% | 43.81 | 5.6 | 7.84% | 18.25% |
ISRG | 82.0B | 6.2B | -4.47% | -13.27% | 61.99 | 13.17 | 8.97% | -22.43% |
EW | 48.3B | 5.4B | 2.41% | -25.12% | 31.77 | 8.98 | 2.86% | 1.25% |
| MID-CAP | ||||||||
PEN | 9.8B | 847.1M | -3.64% | 34.52% | -4.9K | 11.56 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -11.64% | -20.31% | 30.37 | 5.12 | 6.76% | 24.45% |
IART | 4.4B | 1.6B | -8.98% | -18.20% | 24.42 | 2.83 | 0.99% | 6.79% |
IRTC | 3.3B | 410.9M | 4.51% | -3.13% | -28.67 | 8.11 | 27.29% | -14.60% |
STAA | 3.0B | 284.4M | -11.77% | 2.91% | 76.18 | 10.38 | 23.40% | 58.18% |
| SMALL-CAP | ||||||||
BLFS | 917.3M | 154.8M | -6.04% | 0.61% | -8.82 | 5.93 | 60.29% | -2309.58% |
MLAB | 896.3M | 222.4M | -8.27% | -33.23% | -611.78 | 4.03 | 36.07% | -119.34% |
AXDX | 52.5M | 13.1M | -11.48% | -68.24% | -0.74 | 4 | 13.64% | 4.49% |
AEMD | 8.9M | 3.5M | -28.10% | -68.62% | -0.66 | 2.5 | 44.21% | -50.10% |
Financials for Integra LifeSciences Holdings
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -0.5% | 1,558 | 1,565 | 1,567 | 1,559 | 1,542 |
| S&GA Expenses | -1.6% | 616 | 627 | 639 | 641 | 637 |
| Costs and Expenses | -1.3% | 1,319 | 1,336 | 1,346 | 1,346 | 1,345 |
| EBITDA | 5.3% | 263 | 250 | 242 | 236 | - |
| EBITDA Margin | 5.8% | 0.17* | 0.16* | 0.15* | 0.15* | - |
| Earnings Before Taxes | 6.2% | 214 | 201 | 193 | 187 | 215 |
| EBT Margin | 6.7% | 0.14* | 0.13* | 0.12* | 0.12* | - |
| Interest Expenses | 1.6% | 50.00 | 49.00 | 48.00 | 49.00 | 50.00 |
| Net Income | 4.4% | 181 | 173 | 166 | 157 | 169 |
| Net Income Margin | 4.9% | 0.12* | 0.11* | 0.11* | 0.10* | - |
| Free Cahsflow | 15.0% | 222 | 193 | 209 | 237 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 2.2% | 3,890 | 3,807 | 3,753 | 3,672 | 3,782 |
| Current Assets | -2.9% | 1,161 | 1,196 | 1,137 | 1,066 | 1,154 |
| Cash Equivalents | -10.8% | 457 | 512 | 447 | 407 | 513 |
| Inventory | 4.3% | 325 | 311 | 320 | 328 | 317 |
| Net PPE | 3.5% | 311 | 301 | 302 | 309 | 312 |
| Goodwill | 6.2% | 1,039 | 978 | 990 | 1,009 | 1,013 |
| Liabilities | 0.1% | 2,085 | 2,083 | 2,092 | 2,057 | 2,098 |
| Current Liabilities | 5.4% | 321 | 304 | 296 | 316 | 340 |
| Long Term Debt | -1.4% | 810 | 821 | 833 | - | - |
| Shareholder's Equity | 4.6% | 1,804 | 1,724 | 1,661 | 1,615 | 1,685 |
| Retained Earnings | 6.4% | 879 | 826 | 776 | 731 | 699 |
| Additional Paid-In Capital | 0.7% | 1,277 | 1,268 | 1,260 | 1,267 | 1,265 |
| Shares Outstanding | -0.2% | 83.00 | 83.00 | 84.00 | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 6.5% | 264 | 248 | 263 | 288 | 312 |
| Share Based Compensation | -2.5% | 28.00 | 28.00 | 27.00 | 36.00 | 36.00 |
| Cashflow From Investing | -87.5% | -58.58 | -31.24 | -54.52 | -57.94 | -161 |
| Cashflow From Financing | -63.9% | -251 | -153 | -144 | -228 | -98.23 |
| Buy Backs | 0% | 125 | 125 | 125 | 125 | 0.00 |
Risks for IART
What is the probability of a big loss on IART?
63.1%
Probability that Integra LifeSciences Holdings stock will be more than 20% underwater in next one year
48.1%
Probability that Integra LifeSciences Holdings stock will be more than 30% underwater in next one year.
8.5%
Probability that Integra LifeSciences Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IART drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Integra LifeSciences Holdings was unfortunately bought at previous high price.
Drawdowns
Returns for IART
Cumulative Returns on IART
10.9%
10-Year Cumulative Returns
7.2%
7-Year Cumulative Returns
-1.5%
5-Year Cumulative Returns
7.0%
3-Year Cumulative Returns
What are the long-term rolling returns for IART?
FIve years rolling returns for Integra LifeSciences Holdings.
Annualized Returns
Which funds bought or sold IART recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -36.39 | -155,884 | 830,116 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4.09 | 6,000 | 21,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -0.39 | 1,096,780 | 4,541,780 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 9.00 | 1,009 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 9.25 | 1,905,000 | 6,173,000 | 0.06% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 25.00 | 4,543 | 14,543 | -% |
2023-02-21 | KB FINANCIAL PARTNERS, LLC | reduced | -2.65 | 1,000 | 6,000 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -3.01 | 21,125,000 | 95,709,000 | 0.11% |
2023-02-21 | MACQUARIE GROUP LTD | added | 11.81 | 1,250,000 | 6,412,000 | 0.01% |
2023-02-21 | NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | reduced | -35.92 | -66,985 | 377,015 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
IART Alerts
Integra LifeSciences Holdings News
Schedule 13G FIlings of Integra LifeSciences Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | tru st partnership, l.p. | 10.20% | 8,515,930 | SC 13G/A | |
| Feb 13, 2023 | champlain investment partners, llc | 6.30% | 5,259,524 | SC 13G/A | |
| Feb 09, 2023 | morgan stanley | 6.8% | 5,681,483 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.56% | 7,147,759 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 6.84% | 5,709,663 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.6% | 7,143,236 | SC 13G/A | |
| Jul 08, 2022 | capital research global investors | 4.7% | 3,869,770 | SC 13G/A | |
| Feb 14, 2022 | tru st partnership, l.p. | 10.32% | 8,740,930 | SC 13G/A | |
| Feb 11, 2022 | champlain investment partners, llc | 6.72% | 5,694,837 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 9.7% | 8,219,133 | SC 13G/A |
IART Fair Value
Integra LifeSciences Holdings fair value in different scenarios
The table shows the Fair Value estimates for Integra LifeSciences Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 17.17 -67.66% | 20.06 -62.22% | 32.24 -39.27% | 47.72 -10.11% | 59.83 12.70% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Integra LifeSciences Holdings Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Integra LifeSciences Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for IART
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-13 | Schwartz Eric | sold (taxes) | -74,183 | 55.7355 | -1,331 | evp, chief legal officer & sec |
2023-03-13 | DAVIS ROBERT T. JR. | sold (taxes) | -77,284 | 52.61 | -1,469 | evp & president, tt |
2023-03-13 | Evoli Lisa | sold (taxes) | -50,453 | 52.61 | -959 | evp & chro |
2023-03-13 | Mosebrook Jeffrey | sold (taxes) | -10,732 | 52.61 | -204 | svp, fin, pfo & pao |
2023-03-13 | McBreen Michael J. | sold (taxes) | -50,137 | 52.61 | -953 | evp & president, css |
2023-03-12 | Evoli Lisa | sold (taxes) | -51,389 | 52.87 | -972 | evp & chro |
2023-03-12 | Schwartz Eric | sold (taxes) | -61,857 | 52.87 | -1,170 | evp, chief legal officer & sec |
2023-03-12 | Mosebrook Jeffrey | sold (taxes) | -15,385 | 52.87 | -291 | svp, fin, pfo & pao |
2023-03-12 | DAVIS ROBERT T. JR. | sold (taxes) | -86,548 | 52.87 | -1,637 | evp & president, tt |
2023-03-12 | McBreen Michael J. | sold (taxes) | -86,125 | 52.87 | -1,629 | evp & president, css |
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
IART Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Income Statement [Abstract] | |||
| Total revenue, net | $ 1,557,666 | $ 1,542,448 | $ 1,371,868 |
| Costs and expenses: | |||
| Cost of goods sold | 587,355 | 597,808 | 520,834 |
| Research and development | 101,193 | 93,051 | 77,381 |
| Selling, general and administrative | 616,316 | 637,445 | 594,526 |
| Intangible asset amortization | 13,882 | 16,914 | 27,757 |
| Total costs and expenses | 1,318,746 | 1,345,218 | 1,220,498 |
| Operating income | 238,920 | 197,230 | 151,370 |
| Interest income | 11,917 | 6,737 | 9,297 |
| Interest expense | (49,594) | (50,395) | (71,581) |
| Gain from sale of businesses | 644 | 41,798 | 0 |
| Other income, net | 12,007 | 19,307 | 4,434 |
| Income before income taxes | 213,894 | 214,677 | 93,520 |
| Provision (benefit) for income taxes | 33,344 | 45,602 | (40,372) |
| Net income | $ 180,550 | $ 169,075 | $ 133,892 |
| Net income per share | |||
| Basic (in dollars per share) | $ 2.18 | $ 2.00 | $ 1.58 |
| Diluted (in dollars per share) | $ 2.16 | $ 1.98 | $ 1.57 |
| Weighted average common shares outstanding (See Note 13): | |||
| Basic (in shares) | 82,997 | 84,698 | 84,650 |
| Diluted (in shares) | 83,516 | 85,485 | 85,228 |
IART Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 456,661 | $ 513,448 |
| Trade accounts receivable, net of allowances of $4,304 and $4,735 | 263,465 | 231,831 |
| Inventories, net | 324,583 | 317,386 |
| Prepaid expenses and other current assets | 116,789 | 91,051 |
| Total current assets | 1,161,498 | 1,153,716 |
| Property, plant and equipment, net | 311,302 | 311,703 |
| Right of use asset - operating leases | 148,284 | 84,543 |
| Intangible assets, net | 1,126,609 | 1,145,573 |
| Goodwill | 1,038,881 | 1,013,458 |
| Deferred tax assets, net | 45,994 | 56,950 |
| Other assets | 57,190 | 16,440 |
| Total assets | 3,889,758 | 3,782,383 |
| Current Liabilities: | ||
| Current portion of borrowings under senior credit facility | 38,125 | 45,000 |
| Current portion of lease liability - operating leases | 14,624 | 14,775 |
| Accounts payable, trade | 102,100 | 61,837 |
| Contract liabilities | 7,253 | 5,295 |
| Accrued compensation | 78,771 | 92,656 |
| Accrued expenses and other current liabilities | 80,033 | 120,458 |
| Total current liabilities | 320,906 | 340,021 |
| Long-term borrowings under senior credit facility | 733,149 | 824,257 |
| Long-term borrowings under securitization facility | 104,700 | 112,500 |
| Long-term convertible securities | 567,341 | 564,426 |
| Lease liability - operating leases | 157,420 | 90,329 |
| Deferred tax liabilities | 63,338 | 45,788 |
| Other liabilities | 138,501 | 120,258 |
| Total liabilities | 2,085,355 | 2,097,579 |
| Stockholders’ Equity: | ||
| Preferred Stock; no par value; 15,000 authorized shares; none outstanding | 0 | 0 |
| Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December 31, 2022 and 2021, respectively | 905 | 896 |
| Additional paid-in capital | 1,276,977 | 1,264,943 |
| Treasury stock, at cost; 6,823 and 4,899 shares at December 31, 2022 and 2021, respectively | (362,862) | (234,448) |
| Accumulated other comprehensive income (loss) | 10,265 | (45,155) |
| Retained earnings | 879,118 | 698,568 |
| Total stockholders’ equity | 1,804,403 | 1,684,804 |
| Total liabilities and stockholders’ equity | $ 3,889,758 | $ 3,782,383 |